Enliven Therapeutics: appoints new director Kristine Ball

What happened Enliven Therapeutics announced that on Oct 14, 2026 its board increased from 7 to 8 directors and appointed Kristine Ball to serve as a Class II director, with a term expiring at the company’s 2028 annual meeting of stockholders, and as a member of the audit committee, effective Oct 14, 2026.

Key details

• Ms. Ball will receive annual cash compensation of $45,000 for service as an outside director and $10,000 for service as a member of the audit committee.
• As a new outside director, Ms. Ball was granted stock options with a grant date fair value of approximately $650,000; the options vest as to 1/36th of the total shares on each monthly anniversary of the grant date, subject to continued service, and will vest in full upon a Change in Control (as defined in the company’s policy).
• The company entered into its standard form of indemnification agreement with Ms. Ball and disclosed that there are no transactions in which Ms. Ball has an interest requiring disclosure under Item 404(a) of Regulation S-K.
• The company furnished a press release announcing the appointment as Exhibit 99.1 under Item 7.01 (Regulation FD disclosure).

Why it may matter This Form 8-K reports Item 5.02 (departure of directors or certain officers; election of directors), covering the appointment of a director, and Item 7.01 (Regulation FD disclosure), furnishing a press release. The filing does not show why the insider traded or why the company acted.